231 related articles for article (PubMed ID: 18452422)
1. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
6. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
Ohta S; Najima Y; Imamura J
Br J Haematol; 2015 Jun; 169(5):612. PubMed ID: 25855138
[No Abstract] [Full Text] [Related]
8. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Fullmer A; Jabbour E
Am J Hematol; 2010 Mar; 85(3):158-9. PubMed ID: 20131307
[No Abstract] [Full Text] [Related]
10. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: for some difficult cases of adult leukaemia.
Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
[No Abstract] [Full Text] [Related]
12. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib (Sprycel) for CML and Ph + ALL.
Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
[No Abstract] [Full Text] [Related]
14. New approved dasatinib regimen available for clinical use.
Snyder DS
Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
[TBL] [Abstract][Full Text] [Related]
15. Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann OG; Wassmann B; Hoelzer D
Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
[No Abstract] [Full Text] [Related]
16. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fielding AK
Blood; 2010 Nov; 116(18):3409-17. PubMed ID: 20656928
[TBL] [Abstract][Full Text] [Related]
17. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
[TBL] [Abstract][Full Text] [Related]
18. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
19. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Matsue K; Takeuchi M; Koseki M; Uryu H
Ann Hematol; 2006 Aug; 85(8):542-4. PubMed ID: 16570152
[No Abstract] [Full Text] [Related]
20. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
[No Abstract] [Full Text] [Related]
[Next] [New Search]